Rheumatology Billing That Pays What You Earn
Rheumatology billing is dominated by high-cost biologic infusion therapy, joint injection coding, and the complex prior authorization requirements for DMARDs and biologic agents. Infliximab, tocilizumab, and other biologics require meticulous J-code drug billing with payer-specific coverage policies, step therapy documentation, and biosimilar substitution rules. 360Solutions provides rheumatology billing specialists who manage biologic infusion billing, joint aspiration and injection coding, and the dense prior auth workflows that protect your most expensive patient encounters.
Where Rheumatology Practices Lose Revenue
These are the coding and billing pitfalls that cost rheumatology practices the most — and where our specialised billers add the most value.
Biologic Infusion Drug Billing
IV biologic administration requires the infusion administration code (96413 initial; 96415 add-on) plus the J-code drug charge billed in correct units per the administered dose. Drug units must exactly match pharmacy records — any discrepancy flags audit review.
Step Therapy & Auth Documentation
Commercial payers require documented failure of conventional DMARDs (methotrexate, hydroxychloroquine) before approving biologics. Missing step therapy documentation is the top auth denial cause. We maintain treatment history templates for each biologic agent's specific requirements.
Joint Injection & Aspiration Coding
Joint aspiration/injection codes (20600-20611) are tiered by joint size — small, intermediate, or major — and whether imaging guidance was used. Ultrasound-guided injections (76942 add-on) are separately billable when documented. Wrong tier selection causes systematic underpayment.
Biosimilar Substitution Billing
As biosimilars enter the market for adalimumab, infliximab, and etanercept, payers increasingly mandate biosimilar use. Billing the originator brand when a biosimilar is required — or vice versa — causes denial. We track each payer's biosimilar formulary and apply the correct J-code.
High-Risk CPT Groups
Code ranges payers audit most aggressively in Rheumatology.
Common Denial Patterns
Knowing these before submission is the difference between a 60% and a 96% first-pass rate.
Biologic J-code units do not match pharmacy dispense record for administered dose
Step therapy documentation absent — conventional DMARD failure not documented
Joint injection tier (small vs. major joint) does not match joint injected per note
Ultrasound guidance billed without image documentation retained in patient record
Biosimilar J-code required by payer but originator brand J-code submitted
Send us your last 90 days of remittance data — we'll identify your top 3 fixable denial sources at no cost.
Request Free Audit →How 360Solutions Works for Rheumatology Practices
Free 2-Week Billing Audit
We review your last 90 days: denial breakdown by category, AR aging by payer, charge lag, collection rate, and any recurring coding issues specific to your specialty. No commitment required.
Specialty Coder Assignment
You are paired with a coder trained specifically in rheumatology coding. They learn your providers, your documentation patterns, and your payer mix before touching a claim.
Parallel Billing Transition
We run alongside your current billing for 10–14 days with zero cash flow disruption. Claims keep moving during the transition. Your account manager provides daily status updates.
Live KPI Dashboard
Real-time visibility into billed, paid, denied, AR aging, and collection rate — segmented by provider and payer. No black box, no month-end surprises.
Weekly Account Manager Call
Every week your dedicated account manager walks through last week's KPIs, denial trends, and any action items. Critical issues are escalated the same day — not at the next scheduled call.
Questions From Rheumatology Practices
Start With a Free,
No-Obligation Audit
Two weeks, no contract. A certified rheumatology billing specialist reviews your claims, denial patterns, and AR — and shows you exactly what is recoverable.